Peanut allergy is one of the most common type of allergies caused by a legume, known as peanut. The symptoms of the disease include, hives, nausea, stomach cramps, tightness in throat, tingling sensation in or around oral cavity, and rhinorrhea. It has been observed that the patients suffering with asthma and eczema are more likely to get allergy from peanuts. In severe conditions, drop in blood pressure, fainting, swelling in throat, and blockage of airway can also occur.
PEANUT ALLERGY DRUG CANDIDATES IN DEVELOPMENT (2018)
Majority of drug candidates in the pipeline are being manufactured through advanced technologies developed by various educational institutes or companies. Rise in the number of patents approvals and advancements in technologies are the major factors driving the growth of the pipeline.
Some of the other factors enhancing the pipeline growth include; positive clinical as well as Pre-Clinical results of various drug candidates and support from various health organizations such as National Institutes of Health and United States Department of Defense, and educational institutes.
As of March 2018, the peanut allergy therapeutics pipeline comprises of 19 drug candidates in different stages of development. Currently there is no approved drug for the treatment of peanut allergy, leading to a a large unmet need in the its therapeutic pipeline. The lack of any approved medication for the treatment of peanut allergy in the market means that whosoever gets their pipeline drug in the market first, would receive first mover advantage.
Some of the key players involved in the development of peanut allergy therapeutics include Aimmune Therapeutics Inc., DBV Technologies S.A., and AnaptysBio Inc.